These benefits, together with a previous report exhibiting that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like conduct in mice,2 help the principle of focusing on ACKR3 as a novel method to modulate the opioid program, which could open up new therapeutic avenues for opioid-simila